SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-20-048524
Filing Date
2020-04-20
Accepted
2020-04-20 09:12:46
Documents
3
Effectiveness Date
2020-04-20

Document Format Files

Seq Description Document Type Size
1 DEFA14A a20-16225_1defa14a.htm DEFA14A 35302
2 GRAPHIC g162251bci001.jpg GRAPHIC 3890
3 GRAPHIC g162251bci002.gif GRAPHIC 2031
  Complete submission text file 0001104659-20-048524.txt   44794
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36033 | Film No.: 20801525
SIC: 2834 Pharmaceutical Preparations